NDAINJECTIONINJECTABLE
Approved
Nov 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CEFOBID (cefoperazone sodium) is a third-generation cephalosporin antibiotic administered by injection for treatment of serious bacterial infections including respiratory tract, urinary tract, skin, and intra-abdominal infections. It works by inhibiting bacterial cell wall synthesis, making it effective against gram-negative and some gram-positive organisms.
LOE Approaching
Product is in mature/declining phase with moderate competitive pressure (30), indicating smaller brand teams focused on maintenance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CEFOBID offers limited career advancement due to zero linked job openings and mature product lifecycle; positions are primarily defensive, focused on market maintenance and generic competition management. This role suits professionals seeking stable, lower-intensity assignments rather than high-growth opportunities.
Brand ManagerSales Representative
Worked on CEFOBID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.